1. Medtech Insight
  2. >>Archive

News In Brief

Syneron buys UltraShape. Smith & Nephew settles foreign bribery charges. Hospitals settle kyphoplasty allegations. More news briefs.

Aesthetic device maker Syneron Medical Ltd. will gain focused ultrasound fat lipolysis products through its purchase of UltraShape Ltd. for $12 million under a definitive agreement announced Feb. 8. UltraShape’s Contour I V3, available overseas, uses Vertical Dynamic Focus pulsed (non-thermal) focused ultrasound to destroy fat cells, “providing patients a convenient, noninvasive, no-downtime solution to reduce localized fat deposits and body circumference,” Syneron explains. Syneron’s current “leadership position in the body shaping market, which is based on [radiofrequency] induced thermal injury, when complemented by [UltraShape’s] unique fat selective technology, gives physicians a comprehensive body sculpting solution,” said Syneron Chairman Shimon Eckhouse. Israel-based Syneron, which offers a range of aesthetic devices for body contouring, hair removal, wrinkle reduction and skin rejuvenation, expects the deal to close by March 31.

Orthopedic device maker Smith & Nephew PLC will pay $22.2 million to settle foreign bribery charges under agreements announced...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Medtech Will Benefit From Boost To EU’s Quantum Technology Initiative

 
• By Amanda Maxwell

The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By Shubham Singh

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By Marion Webb

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.